Evidence map›Paper›PMID 37047554›Full record

ReviewInternational journal of molecular sciences2023

Multicomponent Reaction-Assisted Drug Discovery: A Time- and Cost-Effective Green Approach Speeding Up Identification and Optimization of Anticancer Drugs.

Giovanni Graziano, Angela Stefanachi, Marialessandra Contino, Rubén Prieto-Díaz, Alessia Ligresti, Poulami Kumar, Antonio Scilimati, Eddy Sotelo, Francesco Leonetti

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. MethodsX · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. A First Diversity-OrientedInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giovanni GrazianoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0002-5575-3240
Angela StefanachiDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0002-9430-7972
Marialessandra ContinoDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0002-0713-3151
Rubén Prieto-DíazCenter for Research in Biological Chemistry and Molecular Materials (CiQUS), Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0003-2539-3106
Alessia LigrestiInstitute of Biomolecular Chemistry, National Research Council of Italy, 80078 Pozzuoli, Italy.ORCID 0000-0003-1787-3900
Poulami KumarInstitute of Biomolecular Chemistry, National Research Council of Italy, 80078 Pozzuoli, Italy.ORCID 0000-0001-7138-218X
Antonio ScilimatiDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0003-2740-6425
Eddy SoteloCenter for Research in Biological Chemistry and Molecular Materials (CiQUS), Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0001-5571-2812
Francesco LeonettiDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.ORCID 0000-0003-2043-7464

Funding

Consellería de Cultura, Educación e Ordenación Universitaria of the Galician Government: (grant: ED431B 2020/43), Centro Singular de Investigación de Galicia accreditation 2019-2022 (ED431G 2019/03) and the European Regional Development Fund (ERDF) (ED431G 2019/03)GENESI" code 092-Prog n. F/180003/03/X43 for the development of innovative radiopharma- ceuticals and biomarkers for the diagnosis of cancers of the male and female reproductive system (2021-2023) code 092-Prog n. F/180003/03/X43Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación-FEDER-UE (PID2020-118511RB-I00 and PID2021-124010OB-100) (PID2020-118511RB-I00 and PID2021-124010OB-100)
6 · The paper itself

Abstract

Multicomponent reactions (MCRs) have emerged as a powerful strategy in synthetic organic chemistry due to their widespread applications in drug discovery and development. MCRs are flexible transformations in which three or more substrates react to form structurally complex products with high atomic efficiency. They are being increasingly appreciated as a highly exploratory and evolutionary tool by the medicinal chemistry community, opening the door to more sustainable, cost-effective and rapid synthesis of biologically active molecules. In recent years, MCR-based synthetic strategies have found extensive application in the field of drug discovery, and several anticancer drugs have been synthesized through MCRs. In this review, we present an overview of representative and recent literature examples documenting different approaches and applications of MCRs in the development of new anticancer drugs.

Indexed as

Antineoplastic AgentsDrug DiscoveryChemistry, OrganicCombinatorial Chemistry TechniquesCost-Benefit AnalysisAntineoplastic Agentsanticancer drugscancerdrug discoverymulticomponent reactions

Identifiers

PMID37047554
PMCPMC10095429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.